Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of BC008-1A Injection in Subjects With Recurrent CNS WHO Grade 4 Glioma.

NCT06773481 is registered in ClinicalTrials.gov with Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06773481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06773481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety and Preliminary Efficacy of BC008-1A Injection in Subjects With Recurrent CNS WHO Grade 4 Glioma.
Lead sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
April 7, 2025
Completion date
December 31, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma who grade iv, glioblastomas (gbm), glioma, glioma tumor recurrence, glioma, recurrent high grade